KEYWORDS atrial flutter/ fibrillation; atrial septal defect; gene; renineangiotensin Background/purpose: Atrial flutter/fibrillation (AFL/Af) is a common late complication in atrial septal defect (ASD) patients even after occluder implantation. We try to delineate the risk factors of persistent AFL/Af. Methods: From 1998 to 2010, all patients older than 18 years of age who received ASD occluder implantation in our hospital were enrolled, and their records were retrospectively reviewed. In addition, renineangiotensin system gene polymorphisms including angiotensinogen gene, A1166C polymorphism on the angiotensin II type I receptor gene, and insertion/deletion (I/D) patterns on the angiotensin-converting enzyme gene were checked using direct sequencing. Results: A total of 517 patients (male/female 127/390) were enrolled. The mean age of patients receiving occluder deployment was 41.5 AE 14.5 years. Prior to occluder deployment, 3.9% of patients had persistent Af, 3.1% of patients had paroxysmal Af, and 0.8% had AFL. After a follow-up of 1894 patient-years, 3.5% had persistent Af and 1.9% of patients had paroxysmal Af. The greatest risk factors of AFL/Af genesis included age, occluder size, presence of multiple ASDs, and underlying thyroid or mitral valve disorder (p < 0.001, p < 0.001, p Z 0.033, p Z 0.016, and p Z 0.012, respectively). Preoperative AFL/Af status is the most important factor in determining AFL/Af resolution and progression after an intervention. The renin eangiotensin system gene polymorphisms had no association with AFL/Af genesis, and progression or resolution after intervention.
Introduction
Atrial septal defect (ASD) is one of the most common congenital heart diseases in the adult population. 1 Prevalence was as high as 3.2/1000 live births in our previous population-based study. 2 Without treatment, the mortality and morbidity rate of hemodynamically significant ASD increases significantly after 25 years of age. 3 ASD occluder implantation is now the mainstay of treatment for hemodynamically significant ASD patients. 4 We reported no procedure mortality and low morbidity in the ASD patients undergoing ASD occluder implantation in 2008. 5 One of the most common late complications of ASD is atrial flutter/ fibrillation (AFL/Af), which may be related to atrial dilatation after a long-term left to right shunt at the atrial level. 6 Without intervention, the prevalence of atrial arrhythmia increases significantly with age, with reported prevalence up to 13% after the age of 40 years, which is significantly higher than that in general population. 7 Although several reports have shown improvement of AFL/Af after ASD repair, either through surgical repair or after ASD occluder implantation, AFL/Af still complicates certain patients with an incidence of 10e25% at the shortterm follow-up. 8, 9 AFL/Af is a common arrhythmia in elderly people. Several recent studies have shown a genetic predisposition, especially in the renineangiotensin system (RAS) gene in Af patients. 10, 11 Angiotensin II activation can trigger the proliferation of fibroblasts and cause myocardial fibrosis. 11, 12 Moreover, RAS gene haplotypes have a strong association with Af. 10 Whether this association exists in these ASD patients remains unknown. Using a large ASD cohort, we attempted to define Af incidence and risk factors in ASD patients receiving occluder deployment. We also tried to identify the role of RAS gene polymorphisms in AFL/Af genesis.
Materials and methods
From 1998 to 2010, all adult patients (>18 years of age) who received ASD occluder implantation in National Taiwan University Hospital were retrospectively included in our study. The occluders we used were Amplatzer septal occluders (AGA Medical Corporation, Plymouth, MN, USA). The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in an a priori approval by the Human Research Committee in National Taiwan University Hospital. The basic clinical characteristics, hemodynamic and cardiac catheterization reports, and follow-up data were collected through a chart review. We evaluated the pre-and postoperative clinical symptoms, electrocardiography (EKG) data, and 24-hour Holter study results. Persistent Af is defined as Af that persists for longer than 7 days (at all available EKG and Holter reports). Paroxysmal Af is defined as self-terminating Af if it ceased spontaneously during the 24-hour Holter examination, or if it did not persist in the whole surface EKG. The cardiac catheterization data, including pulmonary blood flow/systemic blood flow (Qp/Qs), pulmonary artery pressure, and occluder size, were also recorded. For patients with multiple ASDs, either multiple occluders were implanted or one occluder was deployed for the larger hole. For patients with significant pulmonary hypertension, fenestrated occluders were deployed for safety. We considered postoperative AFL/ Af positive when the AFL/Af occurred after discharge. The arrhythmias developing during or immediately after the procedure, but self-terminating thereafter were regarded as negative, as these might relate to the procedure only. Mitral valve disease in our study is defined as more than moderate degree mitral regurgitation or mitral stenosis during echocardiography examination, no matter what the etiology is.
The RAS gene polymorphisms were analyzed after receiving informed consent. Five milliliters of fresh blood were withdrawn and stored in an EDTA tube. Genomic DNA was then extracted. Previously identified I/D polymorphisms on the angiotensin-converting enzyme (ACE) gene; T174M, M235T, G-6A, A-20C, G-152A, and G-217A polymorphisms on the angiotensinogen gene; and A1166C polymorphism on the angiotensin II type I receptor gene were checked using direct sequencing. Previously used primer pairs were used to amplify these exons. 10 A polymerase chain reaction was conducted using 50 ng template DNA, 2.5 pmol primers, 1 mL Mg 2þ (25mM), and 1 mL Master Mix containing deoxyribonucleotide triphosphate (dNTP) and Taq polymerase. Dye terminator sequencing using an ABI 3730 automatic sequencer (Applied Biosystems, Foster City, CA, USA) was then performed. The results were analyzed using the Genotyper program (Life Technologies, San Francisco, CA, USA). The results of the RAS gene haplotypes were compared between those with and without AFL/Af.
Statistical analysis
The data were presented as mean (AEstandard deviation). Student t test was used for a numerical data comparison. The chi-square test and Fisher's exact test were used for a categorical data comparison. Logistic regression was used for multivariate risk factor analysis. Statistical significance was defined as p < 0.05.
Results
In total, 517 ASD patients were enrolled in our study. Male/ female ratio was 127/390. The basic clinical characteristics are shown in Table 1 , and the AFL/Af status is shown in Figure 1 . Prior to occluder deployment, 3.9% of the patients had persistent Af, 3.1% had paroxysmal Af, and 0.8% had AFL (3 of the 4 patients had concomitant paroxysmal Af at Holter examination). The mean interval between the diagnosis of AFL/Af and device placement was 1.5 AE 2.9 years. After a follow-up of 1894 patient-years, 3.5% of the patients had persistent Af and 1.9% had paroxysmal Af after ASD occluder deployment. Two of the 20 patients with persistent Af preoperatively had Af resolution (1 received radiofrequency catheter ablation before occlude deployment and another received cardioversion during occluder implantation) after 5e64 months of followup. For the four patients with AFL before occluder implantation, the AFL improved in all of them (2 received radiofrequency ablation and the other 2 received cardioversion during occluder implantation). For the other 477 patients without preoperative AFL/Af, one progressed to persistent Af after 4.5 years of follow-up. Another five patients had paroxysmal Af during follow-up. Most of the patients with Af received antiarrhythmia medication including beta-blockers, and class Ic or III antiarrhythmia medication both before and after ASD closure.
The AFL/Af risk factor analysis is shown in Table 1 . We identified that an underlying disease (including metabolic syndrome, thyroid dysfunction, and mitral valve disorder), age of cardiac catheterization, mean pulmonary artery pressure, size of the occluders used, multiple ASDs, and fenestrated occluder use all were significant risk factors of AFL/Af either before or after ASD occluder deployment during the follow-up. We then enrolled the significant variables analyzed in univariate regression analysis and performed multivariate regression analysis (Table 1 ). We found that the age of cardiac catheterization, size of the occluders used (corresponding to ASD size), presence of multiple ASDs, and underlying thyroid and mitral valve disorders resulted in a significantly higher risk after adjusting for other variables. We then analyzed the 40 patients with preoperative AFL/Af and attempted to define factors that would cause AFL/Af resolution after ASD occluder implantation. We found that only preoperative AFL/Af status had a significant negative correlation with later AFL/Af improvement (persistent Af vs. AFL or paroxysmal Af, odds ratio 33.8, 95% confidence interval 5.4e210.5, p < 0.001). Excluding preoperative AFL/Af status (i.e., persistent Af vs. AFL or paroxysmal Af), we could not find other factors significantly related to AFL/Af improvement.
We also analyzed the other 477 patients without preoperative AFL/Af and attempted to identify risk factors of AFL/Af progression after occluder implantation. Using a multivariate logistic regression model, we found that the presence of short-run atrial tachycardia during the Holter examination and underlying mitral valve disease were associated with the highest risk of AFL/Af progression with odds ratios of 13.9 (95% confidence interval 1.6e111.1, p Z 0.016) and 236.1 (95% confidence interval 10.5e5320, p Z 0.001), respectively. In addition, multiple occluder implantation and fenestrated occluder use also increased the risk of later AFL/Af progression with odds ratios of 12.4 and 10.9 (p Z 0.045 and 0.084), respectively.
The distribution of RAS gene polymorphisms in 263 ASD patients is shown in Table 2 . The distribution showed no significant difference between those with and without AFL/ Af ( Table 2 ). The RAS haplotypes in these 263 patients are shown in Table 3 . We did not find a significant association between the 16 different haplotypes found in our patients and AFL/Af. We used two-and three-way gene interaction analysis, but we found no significant association between RAS gene polymorphisms and AFL/Af in the ASD patients. We also analyzed those with Af and excluded four AFL patients. There was no association between RAS gene polymorphisms and Af in the ASD patients. We also found that RAS gene polymorphisms had no significant association with AFL/Af resolution in 40 patients with preoperative AFL/Af. In addition, it also showed no significant association with AFL/Af progression in 477 patients without preoperative AFL/Af.
Discussion
Using this large-scale ASD cohort, we found the following:
(1) Older age at the time of intervention, a larger ASD, multiple ASDs, and underlying thyroid and mitral valve disorder can be used to predict AFL/Af genesis. (2) Paroxysmal Af and AFL often resolve after ASD closure, but persistent Af seldom resolves. Preoperative atrial arrhythmia status is the strongest risk factor of later AFL/Af progression or resolution. (3) RAS gene polymorphisms showed no association either with AFL/Af genesis or with the progression or resolution of AFL/Af after ASD intervention. The secundum type of ASD is the most common type of ASD. In the past, open heart surgery was required to correct this congenital heart disease for long-term survival. 3 Currently, most ASDs smaller than 40 mm with adequate rims are corrected through transcatheter ASD occluder deployment, yielding favorable results. 13 Although no randomized clinical trial compares the result of surgical closure and transcatheter closure of ASD, several reports have shown comparable mortality and complication rates between the two groups. Minor morbidity, length of hospital stay and intensive care unit stay, and emotional anxiety are significantly lower in transcatheter approach patients. 13e15 Therefore, transcatheter closure is now the mainstay of ASD treatment: in our hospital, most ASD patients received transcatheter closure rather than an operation. 4, 5 In the general population, the incidence of Af is <0.1% in those younger than 40 years of age and increases gradually with age. The prevalence rate is 1.4% in men and 0.7% in women in our study population older than 40 years of age. 16 In our study, 8.9% of ASD patients have AFL/Af either before or after occluder implantation. The reason for the high incidence of AFL/Af in ASD patients remains unclear. Using multivariate regression analysis, we found that the age of transcatheter closure, size of the device (which corresponded to the size of ASD), presence of multiple ASD, and underlying disorders (thyroid or mitral valve disorder) were the most important AFL/Af genesis risk factors. These results corresponded with those of previous studies. 8, 9, 17 Older age and large or multiple ASDs all resulted in high right atrial wall stress, which then caused right atrial wall thickening and fibrosis. This may be the AFL/Af substrate in ASD patients. This result implied that earlier closure of ASD, especially for those with large and multiple ASDs, is mandatory to prevent the development of Af.
Although several reports have shown an improvement in AFL/Af after ASD repair through surgical repair or ASD occluder implantation, AFL/Af may still pose complications in certain patients. Among them, 8e11.6% experienced a new onset of AFL/Af. 17 In our study, of those with preoperative persistent Af, only 20% had Af improvement. However, of those with preoperative paroxysmal Af, 81.3% had Af improvement, and of those with preoperative AFL, all had AFL resolution. Regression analysis shows that preoperative AFL/Af status was the only significant predictor of AFL/Af resolution. This corresponds with previous reports that persistent AFL/Af seldom improved after ASD closure. However, three of the four patients who received transcatheter ablation for Af either before or after ASD occluder implantation had Af resolution during short-term follow-up. Further studies are needed to investigate whether preoperative transcatheter ablation can eliminate Af.
For those without preoperative AFL/Af, 1.3% still progressed to either paroxysmal or persistent Af after an average 4.5-year follow-up. Multivariate regression analysis revealed that the greatest predictors of later progression were preoperative atrial arrhythmia and underlying mitral valve disorder, followed by multiple occluder implantation and fenestrated occluder use. The result suggests that preoperative atrial arrhythmia is a warning sign of later Af progression, and close follow-up is necessary for these patients. For patients with underlying mitral valve disorder, it is reasonable that Af may progress even after ASD closure because mitral valve disorder is an important risk of Af genesis even in non-ASD patients. 18 In addition, we found that multiple occluder implantation (which often corresponded to a larger ASD and shunt) and more than moderate degree pulmonary hypertension (which corresponded to fenestrated occluder use) are also predictors of later AFL/ Af progression. Therefore, in these patients, close follow- 
The p value of frequency comparing those with and without Af is also shown in the table.
Af Z atrial fibrillation.
up is necessary for early detection and possible intervention.
Af is a common sustained arrhythmia in elderly people. The mechanism is thought to be related to atrial structural remodeling because of atrial dilatation, fibrosis, and electrical remodeling resulting from the shortening of the atrial refractory period. 19 The interaction between genetic and environmental factors was previously believed to contribute to the risk of Af development. In previous studies, several candidate genes such as connexin 40, SCN5A, potassium channel genes, and the RAS genes showed a strong association with Af patients. 10, 11 Among the studied genes, the RAS genes received the most attention. In the animal model with cardiac-restricted ACE expression, mice conveyed severe atrial dilatation and Af. Several other studies have also shown that angiotensin II can trigger a mitogen-activated protein kinase pathway, causing proliferation of the fibroblasts, cardiomyocyte fibrosis, and hypertrophy. 12, 20 In addition, two large-scale caseecontrol studies conducted at our hospital revealed that the specific haplotypes at six loci (T174M, M235T, G-6A, A-20C, G-152A, and G-217A) of angiotensinogen, combined with haplotypes at ACE and angiotensin II type I receptor gene, had a strong association with Af patients. This implied that RAS gene polymorphisms may predispose the genesis of lone Af when accompanied by environmental factors. 10 However, in our current study, RAS gene polymorphisms did not show any association with the genesis, progression, or resolution of Af in ASD patients. Therefore, Af development in these ASD patients may be relatively different from that in patients with lone Af. 21 This result implies that the RAS blocker, as an ACE inhibitor, may have no effect on the prevention of Af in these ASD patients.
In patients with lone Af, the pulmonary vein is considered the most important focus for arrhythmia. In ASD patients, because right atrial dilatation is the pathognomonic feature, the Af foci should be different from those with lone Af, and were previously considered at the right atrium. Several reports have been proposed on the resolution of chronic Af after right atrial separation in ASD patients. 22 However, a recent report suggested that the right atrial maze had a lower long-term arrhythmia-free survival rate compared with the biatrial maze. 23 Therefore, they suggested that the anatomical and molecular mechanisms of ASD patients were complex, and the right atrial dilatation and pulmonary vein foci may all play some roles. In our study, we found that the mitral valve disorder was an important risk factor of later atrial arrhythmia progression. This suggested that not all cases of Af in ASD patients are related to right atrial dilatation. Some of the Af in ASD patients may relate to left atrial dilatation secondary to mitral valve disorder. In addition, of the four patients who received pulmonary vein foci ablation for Af, the Af resolved in three patients at short-term follow-up. This also supported that the pulmonary vein foci may also be important in these ASD patients. Further study is warranted to determine if the pulmonary vein isolation before ASD occluder deployment can cause later Af regression.
As a retrospective study, not all our patients had 24-hour Holter EKG data (only 11/20 patients had preoperative 24hour Holter study) before occluder implantation, but all our patients with Af underwent postoperative 24-hour Holter examination. For those without preoperative 24-hour Holter data, we could only define the preoperative Af status according to all available EKG data at clinics, and EKG monitoring data during admission and cardiac catheterization. This may decrease the study power of our study.
In conclusion, AFL/Af is a common late complication in hemodynamically significant ASD patients, and it occurred in 8.9% of the patients in our long-term follow-up. Older age at the time of ASD closure, a larger ASD, existence of multiple ASDs, and underlying thyroid or mitral valve disorder are significant indicators of AFL/Af occurrence. Preimplantation atrial arrhythmia predicted later Af progression and resolution. RAS gene polymorphisms were not associated with AFL/Af in ASD patients.
